Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and nvp-aew541

lapatinib has been researched along with nvp-aew541 in 2 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(nvp-aew541)		Trials
(nvp-aew541)		Recent Studies (post-2010) (nvp-aew541)
1,9193051,44295061

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)nvp-aew541 (IC50)
3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)8.9
Epidermal growth factor receptorHomo sapiens (human)5.2
Insulin receptorHomo sapiens (human)0.7885
Tyrosine-protein kinase LckHomo sapiens (human)5.6
Tyrosine-protein kinase LynHomo sapiens (human)1.4
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)3.3
Insulin-like growth factor 1 receptorHomo sapiens (human)0.0534
Mast/stem cell growth factor receptor KitHomo sapiens (human)6.3
Fibroblast growth factor receptor 1Homo sapiens (human)4.3
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)4
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.8
Fibroblast growth factor receptor 2Homo sapiens (human)2.7
Fibroblast growth factor receptor 4Homo sapiens (human)5
Vascular endothelial growth factor receptor 2Homo sapiens (human)7.1
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)1.4
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)3.2
Activin receptor type-1Homo sapiens (human)2.9
Tyrosine-protein kinase BTKHomo sapiens (human)7.6
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.13
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)1.7

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abraham, J; Efstratiadis, A; Giles, FG; Keller, C; Kilcoyne, A; LeGallo, RD; Malempati, S; McCleish, AT; Nelon, LD; Nishijo, K; Nowak, BM; Prajapati, SI; Rubin, BP; Schaffer, BS; Taniguchi, E1
Engelke, LH; Gohr, K; Hamacher, A; Kassack, MU1

Other Studies

2 other study(ies) available for lapatinib and nvp-aew541

ArticleYear
Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:4

    Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Child; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Embryo, Mammalian; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Phosphorylation; Pyrimidines; Pyrroles; Quail; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma; RNA Interference; Tumor Burden; Tumor Cells, Cultured; Young Adult

2011
Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    BMC cancer, 2017, Nov-03, Volume: 17, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms

2017